Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud (Q54322103)
Jump to navigation
Jump to search
scientific article published in December 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud |
scientific article published in December 2014 |
Statements
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud (English)
1 reference
Désirée van der Heijde
1 reference
Arthur Kavanaugh
1 reference
Michael E Weinblatt
1 reference
Mark C Genovese
1 reference
Meilien Ho
1 reference
Sally Hollis
1 reference
Krystyna Rosiak-Jedrychowicz
1 reference
David S Millson
1 reference
Gustavo Leon
1 reference
Millie Wang
1 reference
1 December 2014
1 reference
66
1 reference
12
1 reference
3255-3264
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference